Additionally, in the retrospective IMMUNOTARGET registry trial, patients with NSCLC with HER2 exon 20 mutations treated with immune checkpoint inhibitor (ICI) monotherapy had an ORR of 7% and a median PFS of 2.5 months111. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.